Gilead Sciences, Inc. (NASDAQ:GILD)‘s stock had its “outperform” rating reaffirmed by analysts at Cowen and Company in a report released on Thursday. They currently have a $90.00 price target on the biopharmaceutical company’s stock. Cowen and Company’s price objective would suggest a potential upside of 20.06% from the stock’s current price.

Several other analysts also recently issued reports on the stock. Vetr raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $74.58 price objective for the company in a research report on Tuesday, April 18th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $82.00 price objective on shares of Gilead Sciences in a research report on Thursday, April 6th. J P Morgan Chase & Co reaffirmed an “overweight” rating and issued a $82.00 price objective on shares of Gilead Sciences in a research report on Thursday, April 6th. Zacks Investment Research raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $76.00 price objective for the company in a research report on Tuesday, May 2nd. Finally, Barclays PLC reaffirmed an “overweight” rating and issued a $85.00 price objective (down previously from $90.00) on shares of Gilead Sciences in a research report on Sunday, April 23rd. Fourteen equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company. Gilead Sciences currently has a consensus rating of “Buy” and an average price target of $80.46.

Gilead Sciences (NASDAQ:GILD) traded up 1.04% on Thursday, reaching $74.96. 13,870,979 shares of the company’s stock traded hands. The stock has a 50-day moving average of $69.34 and a 200 day moving average of $68.59. Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $82.10. The firm has a market capitalization of $97.95 billion, a P/E ratio of 7.92 and a beta of 1.21. Gilead Sciences also was the recipient of some unusual options trading activity on Wednesday. Traders bought 23,892 put options on the stock. This represents an increase of approximately 241% compared to the typical daily volume of 7,005 put options.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 43.42% and a return on equity of 76.64%. The firm had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. During the same quarter last year, the firm posted $3.08 earnings per share. Gilead Sciences’s revenue for the quarter was down 8.2% compared to the same quarter last year. On average, equities analysts expect that Gilead Sciences will post $8.42 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Gilead Sciences, Inc. (NASDAQ:GILD) Given “Outperform” Rating at Cowen and Company” was reported by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/07/27/gilead-sciences-inc-nasdaqgild-given-outperform-rating-at-cowen-and-company.html.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the sale, the insider now directly owns 3,199,969 shares in the company, valued at $227,197,799. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $71.06, for a total transaction of $355,300.00. Following the completion of the sale, the executive vice president now owns 102,988 shares in the company, valued at $7,318,327.28. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 128,276 shares of company stock worth $9,190,610. Company insiders own 1.30% of the company’s stock.

A number of large investors have recently modified their holdings of GILD. Grandfield & Dodd LLC boosted its stake in shares of Gilead Sciences by 114.2% in the second quarter. Grandfield & Dodd LLC now owns 101,903 shares of the biopharmaceutical company’s stock valued at $7,213,000 after buying an additional 54,321 shares during the period. David R. Rahn & Associates Inc. acquired a new stake in shares of Gilead Sciences during the second quarter valued at approximately $816,000. Nwam LLC boosted its stake in shares of Gilead Sciences by 5.0% in the second quarter. Nwam LLC now owns 13,020 shares of the biopharmaceutical company’s stock valued at $922,000 after buying an additional 616 shares during the period. CIBC Asset Management Inc boosted its stake in shares of Gilead Sciences by 4.5% in the second quarter. CIBC Asset Management Inc now owns 165,663 shares of the biopharmaceutical company’s stock valued at $11,726,000 after buying an additional 7,093 shares during the period. Finally, Honkamp Krueger Financial Services Inc. boosted its stake in shares of Gilead Sciences by 7.6% in the second quarter. Honkamp Krueger Financial Services Inc. now owns 21,049 shares of the biopharmaceutical company’s stock valued at $1,490,000 after buying an additional 1,493 shares during the period. Hedge funds and other institutional investors own 74.05% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.